AKT1 and head and neck squamous cell carcinoma: In our two SCCHN cell lines, cetuximab exposure led to negative regulation of the PI3K/Akt and MAPK pathways, although the activation of these pathways has sometimes been incriminated as a resistance mechanism to EGFR inhibitors in SCCHN [51,52].